AURO LABORATORIES
|
AURO LABORATORIES Last 5 Year Financial Ratios History
[Standalone]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 5.67 | 2.95 | 12.50 | 3.92 | 4.56 |
| CEPS(Rs) | 10.18 | 4.71 | 14.26 | 5.64 | 6.20 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 74.36 | 68.94 | 67.32 | 54.87 | 50.58 |
| Tax Rate(%) | 26.52 | 2.24 | 24.68 | 29.13 | 26.57 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 32.55 | 16.36 | 19.89 | 8.30 | 9.09 |
| EBIT Margin(%) | 29.48 | 15.50 | 20.66 | 8.05 | 9.24 |
| Pre Tax Margin(%) | 15.64 | 9.84 | 19.29 | 6.51 | 7.62 |
| PAT Margin (%) | 11.49 | 9.61 | 14.53 | 4.62 | 5.59 |
| Cash Profit Margin (%) | 20.63 | 15.35 | 16.56 | 6.65 | 7.59 |
| Performance Ratios | |||||
| ROA(%) | 3.21 | 1.99 | 11.00 | 4.40 | 5.87 |
| ROE(%) | 7.91 | 4.33 | 20.46 | 7.43 | 9.47 |
| ROCE(%) | 9.17 | 3.79 | 20.37 | 9.92 | 12.20 |
| Asset Turnover(x) | 0.28 | 0.21 | 0.76 | 0.95 | 1.05 |
| Sales/Fixed Asset(x) | 0.49 | 0.53 | 1.74 | 2.08 | 2.05 |
| Working Capital/Sales(x) | 13.91 | -24.74 | 7.75 | 3.02 | 2.95 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 2.04 | 1.89 | 0.57 | 0.48 | 0.49 |
| Receivable days | 110.10 | 217.45 | 87.78 | 89.77 | 75.03 |
| Inventory Days | 102.16 | 113.63 | 68.04 | 55.24 | 24.40 |
| Payable days | 327.89 | 246.16 | 121.53 | 83.56 | 59.08 |
| Valuation Parameters | |||||
| PER(x) | 46.75 | 78.15 | 12.89 | 13.95 | 21.98 |
| PCE(x) | 26.04 | 48.96 | 11.30 | 9.68 | 16.19 |
| Price/Book(x) | 3.56 | 3.34 | 2.39 | 1.00 | 1.98 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 7.38 | 9.83 | 2.33 | 0.72 | 1.26 |
| EV/Core EBITDA(x) | 18.88 | 46.33 | 10.27 | 7.13 | 11.18 |
| EV/EBIT(x) | 25.03 | 63.47 | 11.28 | 8.93 | 13.59 |
| EV/CE(x) | 2.07 | 2.14 | 1.83 | 0.94 | 1.16 |
| M Cap / Sales | 5.37 | 7.51 | 1.87 | 0.64 | 1.23 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 60.74 | -64.34 | 1.40 | 3.99 | -6.24 |
| Core EBITDA Growth(%) | 195.98 | -66.65 | 128.22 | -6.71 | -52.35 |
| EBIT Growth(%) | 205.78 | -73.26 | 160.13 | -9.37 | -57.13 |
| PAT Growth(%) | 92.14 | -76.40 | 219.09 | -14.15 | -60.38 |
| EPS Growth(%) | 92.14 | -76.40 | 219.09 | -14.15 | -60.38 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 1.37 | 1.05 | 0.63 | 0.19 | 0.44 |
| Current Ratio(x) | 1.08 | 0.96 | 1.29 | 1.97 | 1.86 |
| Quick Ratio(x) | 0.60 | 0.79 | 0.94 | 1.32 | 1.64 |
| Interest Cover(x) | 2.13 | 2.74 | 15.06 | 5.23 | 5.69 |
| Total Debt/Mcap(x) | 0.38 | 0.31 | 0.26 | 0.19 | 0.22 |
Compare Financial Ratios of peers of AURO LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AURO LABORATORIES | ₹147.5 Cr | 1.4% | -4.8% | -12.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹467,630.0 Cr | -2.6% | 2.4% | 14.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹221,666.0 Cr | 6.5% | 23.3% | 25.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹190,108.0 Cr | 2.6% | 3% | 33.5% | Stock Analytics | |
| CIPLA | ₹117,139.0 Cr | -1.1% | -0.2% | -7.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,990.9 Cr | 2.6% | -13.3% | -10.7% | Stock Analytics | |
AURO LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AURO LABORATORIES | 1.4% |
-4.8% |
-12.5% |
| SENSEX | 1.2% |
0.4% |
-2.9% |
You may also like the below Video Courses
